Abstract
Objective To investigate folate-receptor 1 (FOLR1) expression in ovarian cancer and its association with patient prognosis.
Methods TCGA and Oncomine databases were used to collect data about FOLR1 mRNA expression in multiple carcinomas. FOLR1 mRNA expression levels in ovarian cancer samples and corresponding adjacent normal ovary tissue were compared. A protein-protein interaction (PPI) network was constructed using the STRING database of FOLR1 and relevant genes. The overall survival (OS) and progression free survival (PFS) rates of ovarian cancer patients in high- and low- FOLR1 expression groups were compared by log-rank test. Sixty-six ovarian epithelial carcinoma samples were included in the study, and tumor specimens of the 66 cases were tested for FOLR1 protein expression by an immunohistochemistry assay.
Results FOLR1 mRNA was significantly elevated in ovarian cancer compared to other carcinomas. FOLR1 mRNA expression levels were significantly higher in tumor tissues than in the corresponding normal tissues (P<0.05) of ovarian cancer patients. The PPI network indicated that the local clustering coefficient was 0.898, indicating that the PPI network was enriched significantly (P<0.05). The median PFS values were 22.39 and 19.00 months for lowand high-FOLR1 expression groups, respectively, with significant statistical difference between the two (HR=1.26, 95%CI:1.09-1.45, P<0.05). FOLR1 protein expression was correlated with tumor differentiation (P<0.05) in ovarian cancer patients. However, its levels were not correlated with patient age, tumor diameter, lymph node metastasis or FIGO stage (P>0.05).
Conclusion FOLR1 is upregulated in epithelial ovarian cancer, and its expression is correlated with patients’ progression free survival, making it a valuable biomarker for prognosis.
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.10.3322/caac.21551Search in Google Scholar PubMed
2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284–96.10.3322/caac.21456Search in Google Scholar PubMed PubMed Central
3. KRAUL L. Krebsarzt. 1952;7:289–91.Search in Google Scholar
4. Liu J, Meng H, Li S, Shen Y, Wang H, Shan W, et al. Identification of Potential Biomarkers in Association With Progression and Prognosis in Epithelial Ovarian Cancer by Integrated Bioinformatics Analysis. Front Genet. 2019 Oct;10:1031.10.3389/fgene.2019.01031Search in Google Scholar PubMed PubMed Central
5. Cipriano NM Jr, de Brito AM, de Oliveira ES, de Faria FC, Lemos S, Rodrigues AN, et al. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil. Breast Cancer. 2019 May;26(3):397–405.10.1007/s12282-018-00938-zSearch in Google Scholar PubMed
6. Hu J, Liu Z, Wang X. Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism? Med Hypotheses. 2013 Oct;81(4):515–20.10.1016/j.mehy.2013.06.009Search in Google Scholar PubMed
7. Havrilesky L, Darcy M, Hamdan H, Priore RL, Leon J, Bell J, et al.; Gynecologic Oncology Group Study. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003 Oct;21(20):3814–25.10.1200/JCO.2003.11.052Search in Google Scholar PubMed
8. Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. Clin Biochem. 2013 Oct;46(15):1462–8.10.1016/j.clinbiochem.2013.03.010Search in Google Scholar PubMed PubMed Central
9. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses [J]. Nucleic Acids Res. 2017 Jul;45 W1:W98–102.10.1093/nar/gkx247Search in Google Scholar PubMed PubMed Central
10. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets [J]. Nucleic Acids Res. 2019 Jan;47 D1:D607–13.10.1093/nar/gky1131Search in Google Scholar PubMed PubMed Central
11. Vitale SG, Capriglione S, Zito G, Lopez S, Gulino FA, Di Guardo F, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Arch Gynecol Obstet. 2019 Feb;299(2):299–315.10.1007/s00404-018-5006-zSearch in Google Scholar PubMed
12. Schuurman MS, Kruitwagen RF, Portielje JE, Roes EM, Lemmens VE, van der Aa MA. Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis. Gynecol Oncol. 2018 May;149(2):270–4.10.1016/j.ygyno.2018.02.017Search in Google Scholar PubMed
13. Schmid G, Notaro S, Reimer D, Abdel-Azim S, Duggan-Peer M, Holly J, et al. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. BMC Cancer. 2016 Feb;16(1):102.10.1186/s12885-016-2135-2Search in Google Scholar PubMed PubMed Central
14. Liu C, Ding L, Bai L, Chen X, Kang H, Hou L, et al. Folate receptor alpha is associated with cervical carcinogenesis and regulates cervical cancer cells growth by activating ERK1/2/c-Fos/c-Jun. Biochem Biophys Res Commun. 2017 Sep;491(4):1083–91.10.1016/j.bbrc.2017.08.015Search in Google Scholar PubMed
15. Boogerd LS, Hoogstins CE, Gaarenstroom KN, de Kroon CD, Beltman JJ, Bosse T, et al. Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. Oncotarget. 2017 Dec;9(1):791–801.10.18632/oncotarget.23155Search in Google Scholar PubMed PubMed Central
16. Shen J, Hu Y, Putt KS, Singhal S, Han H, Visscher DW, et al. Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Oncotarget. 2017 Dec;9(4):4485–95.10.18632/oncotarget.23321Search in Google Scholar PubMed PubMed Central
17. Omote S, Takata K, Tanaka T, Miyata-Takata T, Ayada Y, Noujima-Harada M, et al. Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients. Med Mol Morphol. 2018 Dec;51(4):237–43.10.1007/s00795-018-0197-8Search in Google Scholar PubMed
18. Pérez-Ramírez C, Cañadas-Garre M, Alnatsha A, Villar E, Delgado JR, Calleja-Hernández MÁ, et al. Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer. Pathol Res Pract. 2018 Jan;214(1):44–52.10.1016/j.prp.2017.11.015Search in Google Scholar PubMed
19. Zhao H, Zeng X. Clinical influence of maternal serum homocysteine, folate and vitamin B12 in the development of preeclampsia. Pteridines. 2019;30(1):48–53.10.1515/pteridines-2019-0006Search in Google Scholar
20. Wei Q, Shen H, Wang LE, Duphorne CM, Pillow PC, Guo Z, et al. Association between low dietary folate intake and suboptimal cellular DNA repair capacity. Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):963–9.Search in Google Scholar
21. Cheung A, Opzoomer J, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, et al. Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. Clin Cancer Res. 2018 Oct;24(20):5098–111.10.1158/1078-0432.CCR-18-0652Search in Google Scholar PubMed PubMed Central
22. Ginter PS, McIntire PJ, Cui X, Irshaid L, Liu Y, Chen Z, et al. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer. Clin Breast Cancer. 2017 Nov;17(7):544–9.10.1016/j.clbc.2017.03.007Search in Google Scholar PubMed
23. Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016 Aug;7(32):52553–74.10.18632/oncotarget.9651Search in Google Scholar PubMed PubMed Central
24. Farran B, Albayrak S, Abrams J, Tainsky MA, Levin NK, Morris R, et al. Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance. Cancer Med. 2019 Mar;8(3):920–7.10.1002/cam4.1944Search in Google Scholar PubMed PubMed Central
25. Kurosaki A, Hasegawa K, Kato T, Abe K, Hanaoka T, Miyara A, et al. Serum folate receptor alpha as a biomarker for ovarian cancer: implications for diagnosis, prognosis and predicting its local tumor expression. Int J Cancer. 2016 Apr;138(8):1994–2002.10.1002/ijc.29937Search in Google Scholar PubMed
26. D’Angelica M, Ammori J, Gonen M, Klimstra DS, Low PS, Murphy L, et al. Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. Mod Pathol. 2011 Sep;24(9):1221–8.10.1038/modpathol.2011.82Search in Google Scholar PubMed
27. Boogerd LS, Boonstra MC, Beck AJ, Charehbili A, Hoogstins CE, Prevoo HA, et al. Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients. Oncotarget. 2016 Apr;7(14):17442–54.10.18632/oncotarget.7856Search in Google Scholar PubMed PubMed Central
28. Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, et al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One. 2009 Jul;4(7):e6292.10.1371/journal.pone.0006292Search in Google Scholar PubMed PubMed Central
29. Laganà AS, Sofo V, Vitale SG, Triolo O. Epithelial ovarian cancer inherent resistance: may the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role? Gynecol Oncol Rep. 2016 Sep;18:57–8.10.1016/j.gore.2016.09.004Search in Google Scholar PubMed PubMed Central
30. Laganà AS, Colonese F, Colonese E, Sofo V, Salmeri FM, Granese R, et al. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. Eur J Gynaecol Oncol. 2015;36(5):495–505.Search in Google Scholar
© 2020 Yan Wang et al., published by De Gruyter
This work is licensed under the Creative Commons Attribution 4.0 International License.
